What is Leerink Partnrs’ Forecast for Vaxcyte Q1 Earnings?

Vaxcyte, Inc. (NASDAQ:PCVX) – Equities research analysts at Leerink Partnrs cut their Q1 2025 EPS estimates for Vaxcyte in a note issued to investors on Tuesday, April 1st. Leerink Partnrs analyst D. Risinger now expects that the company will post earnings of ($1.07) per share for the quarter, down from their prior estimate of ($1.01). The consensus estimate for Vaxcyte’s current full-year earnings is ($4.21) per share. Leerink Partnrs also issued estimates for Vaxcyte’s Q2 2025 earnings at ($1.18) EPS, Q3 2025 earnings at ($1.23) EPS, Q4 2025 earnings at ($1.37) EPS, FY2025 earnings at ($4.85) EPS, FY2026 earnings at ($5.50) EPS, FY2027 earnings at ($5.59) EPS, FY2028 earnings at ($4.68) EPS and FY2029 earnings at $0.46 EPS.

Vaxcyte (NASDAQ:PCVX) last issued its earnings results on Tuesday, February 25th. The company reported ($1.02) earnings per share for the quarter, topping the consensus estimate of ($1.16) by $0.14.

A number of other analysts also recently issued reports on PCVX. Guggenheim reissued a “buy” rating and set a $160.00 target price on shares of Vaxcyte in a research report on Wednesday, March 12th. Evercore ISI raised shares of Vaxcyte to a “strong-buy” rating in a research report on Monday, March 31st. Bank of America reduced their target price on shares of Vaxcyte from $157.00 to $137.00 and set a “buy” rating on the stock in a report on Tuesday. The Goldman Sachs Group lowered their price target on Vaxcyte from $138.00 to $100.00 and set a “buy” rating for the company in a report on Tuesday. Finally, Needham & Company LLC reduced their price objective on Vaxcyte from $140.00 to $90.00 and set a “buy” rating on the stock in a research note on Tuesday. Nine equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Vaxcyte currently has a consensus rating of “Buy” and a consensus target price of $136.50.

Vaxcyte Price Performance

Shares of NASDAQ:PCVX opened at $31.60 on Thursday. The business has a 50-day moving average of $74.59 and a two-hundred day moving average of $89.85. The firm has a market capitalization of $4.07 billion, a PE ratio of -6.87 and a beta of 1.26. Vaxcyte has a 12 month low of $29.57 and a 12 month high of $121.06.

Insider Buying and Selling at Vaxcyte

In other Vaxcyte news, Director Teri Loxam sold 6,250 shares of the company’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $85.11, for a total value of $531,937.50. Following the transaction, the director now directly owns 7,175 shares of the company’s stock, valued at $610,664.25. This represents a 46.55 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, COO Jim Wassil sold 8,000 shares of the firm’s stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $86.22, for a total transaction of $689,760.00. Following the sale, the chief operating officer now directly owns 205,695 shares of the company’s stock, valued at $17,735,022.90. The trade was a 3.74 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 38,250 shares of company stock valued at $3,170,738 in the last ninety days. Insiders own 3.10% of the company’s stock.

Hedge Funds Weigh In On Vaxcyte

Several large investors have recently modified their holdings of the stock. California State Teachers Retirement System lifted its holdings in Vaxcyte by 17.5% during the 4th quarter. California State Teachers Retirement System now owns 105,052 shares of the company’s stock worth $8,600,000 after buying an additional 15,616 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in Vaxcyte during the fourth quarter worth $8,487,000. Forum Financial Management LP bought a new position in Vaxcyte during the fourth quarter worth $255,000. GF Fund Management CO. LTD. acquired a new position in Vaxcyte in the fourth quarter worth $214,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Vaxcyte by 15.8% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 472,964 shares of the company’s stock valued at $38,717,000 after purchasing an additional 64,690 shares during the last quarter. Institutional investors own 96.78% of the company’s stock.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.